ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "CAR T Cells Halt Atherosclerosis 11/21/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis.
Article Links:
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. (Circulation)
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age. (JAMA cardiology)
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. (Heart (British Cardiac Society))
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. (Heart (British Cardiac Society))
Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/
Featured Articles
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268661
Summary: This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259058
Summary: This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41266240
Summary: A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41218924
Summary: This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.
Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41218925
Summary: This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study’s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group.
Transcript
Today’s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.
Article number two. Blood Pressure in Adolescence and Atherosclerosis in Middle Age. This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.
Article number three. Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.
Article number four. Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.
Article number five. Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study’s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group.
Thank you for listening. Don’t forget to subscribe.
Keywords
mortality, blood pressure, infective endocarditis, medical therapy, cardiovascular disease, chimeric antigen receptor T regulatory cells, oxidized low-density lipoprotein, plaque development, heart failure, atherosclerosis, cardiac implantable electronic devices, percutaneous coronary interventions, diagnostic criteria, adolescence, European Society of Cardiology, older patients, left-sided endocarditis, percutaneous ventricular assist devices, valve surgery, Duke-International Society for Cardiovascular Infectious Diseases, hemodynamic support, Staphylococcus aureus infective endocarditis, middle age.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post CAR T Cells Halt Atherosclerosis 11/21/25 first appeared on Cardiology Today.
Article Links:
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. (Circulation)
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age. (JAMA cardiology)
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. (Heart (British Cardiac Society))
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. (Heart (British Cardiac Society))
Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/
Featured Articles
Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268661
Summary: This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.
Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259058
Summary: This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.
Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41266240
Summary: A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.
Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41218924
Summary: This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.
Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41218925
Summary: This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study’s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group.
Transcript
Today’s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment.
Article number two. Blood Pressure in Adolescence and Atherosclerosis in Middle Age. This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk.
Article number three. Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis.
Article number four. Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application.
Article number five. Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. This target trial emulation investigated the utility of percutaneous ventricular assist devices for hemodynamic support during percutaneous coronary interventions (P. C. I.) in older patients with heart failure (H. F.). The study’s results demonstrated the specific outcomes associated with percutaneous ventricular assist device use in Medicare beneficiaries aged 65 to 99 years who had systolic H. F. and coronary artery disease. These findings provide crucial data to inform clinical decision-making for P. C. I. in this high-risk patient group.
Thank you for listening. Don’t forget to subscribe.
Keywords
mortality, blood pressure, infective endocarditis, medical therapy, cardiovascular disease, chimeric antigen receptor T regulatory cells, oxidized low-density lipoprotein, plaque development, heart failure, atherosclerosis, cardiac implantable electronic devices, percutaneous coronary interventions, diagnostic criteria, adolescence, European Society of Cardiology, older patients, left-sided endocarditis, percutaneous ventricular assist devices, valve surgery, Duke-International Society for Cardiovascular Infectious Diseases, hemodynamic support, Staphylococcus aureus infective endocarditis, middle age.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post CAR T Cells Halt Atherosclerosis 11/21/25 first appeared on Cardiology Today.
In God we trust